72 related articles for article (PubMed ID: 15184821)
21. Prediction of sustained virological response in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) and ribavirin.
Foster GR; Fried MW; Hadziyannis SJ; Messinger D; Freivogel K; Weiland O
Scand J Gastroenterol; 2007 Feb; 42(2):247-55. PubMed ID: 17327945
[TBL] [Abstract][Full Text] [Related]
22. Hepatitis C virus RNA kinetics during the initial 12 weeks treatment with pegylated interferon-alpha 2a and ribavirin according to virological response.
Carlsson T; Reichard O; Norkrans G; Bläckberg J; Sangfelt P; Wallmark E; Weiland O
J Viral Hepat; 2005 Sep; 12(5):473-80. PubMed ID: 16108761
[TBL] [Abstract][Full Text] [Related]
23. Early HCV RNA changes in patients with chronic hepatitis C treated with peginterferon alfa 2b and ribavirin.
Gallegos-Orozco JF; Fuentes AP; Olivera-Martinez MA; Gutiérrez-Reyes G; Cortina D; Oregel JA; Pérez-Pruna C; Sixtos MS; Cruz-Castellanos S; Soto-Ramírez LE; Rodríguez-Díaz R; Fuentes-Romero L; Gutiérrez-Ruiz MC; Kershenobich D
Rev Invest Clin; 2003; 55(2):138-42. PubMed ID: 12827916
[TBL] [Abstract][Full Text] [Related]
24. Heterogeneous virologic response rates to interferon-based therapy in patients with chronic hepatitis C: who responds less well?
Zeuzem S
Ann Intern Med; 2004 Mar; 140(5):370-81. PubMed ID: 14996679
[TBL] [Abstract][Full Text] [Related]
25. Treatment options for nonresponders and relapsers to initial therapy for hepatitis C.
Duncan M; Younossi Z
Cleve Clin J Med; 2003 Sep; 70 Suppl 4():S21-6. PubMed ID: 14558642
[TBL] [Abstract][Full Text] [Related]
26. Hepatitis C treatment update.
Pearlman BL
Am J Med; 2004 Sep; 117(5):344-52. PubMed ID: 15336584
[TBL] [Abstract][Full Text] [Related]
27. Nonresponse to treatment for hepatitis C: current management strategies.
Yuan HJ; Lee WM
Drugs; 2008; 68(1):27-42. PubMed ID: 18081371
[TBL] [Abstract][Full Text] [Related]
28. Hepatitis C: current options for nonresponders to peginterferon and ribavirin.
Thomas E; Fried MW
Curr Gastroenterol Rep; 2008 Feb; 10(1):53-9. PubMed ID: 18417043
[TBL] [Abstract][Full Text] [Related]
29. Thymalfasin for the treatment of chronic hepatitis C infection.
Rustgi VK
Expert Rev Anti Infect Ther; 2005 Dec; 3(6):885-92. PubMed ID: 16307501
[TBL] [Abstract][Full Text] [Related]
30. Nonresponse to interferon in chronic hepatitis C: re-treatment redux.
Koff R
JAMA; 2001 Jan; 285(2):212-4. PubMed ID: 11176816
[No Abstract] [Full Text] [Related]
31. Assessment of the patient who failed treatment for chronic hepatitis C.
Levine CD; Ghalib RH
Gastroenterol Nurs; 2005; 28(3 Suppl):S24-30. PubMed ID: 15976557
[TBL] [Abstract][Full Text] [Related]
32. Management of chronic hepatitis C treatment failures: role of consensus interferon.
Gonzalez SA; Keeffe EB
Biologics; 2009; 3():141-50. PubMed ID: 19707403
[TBL] [Abstract][Full Text] [Related]
33. Hepatitis C virus genotype 3: hope for nonresponders and patients with cirrhosis.
Shalimar
J Clin Exp Hepatol; 2014 Jun; 4(2):179-81. PubMed ID: 25755556
[No Abstract] [Full Text] [Related]
34. Treatment options of patients with chronic hepatitis C who have failed prior therapy.
Shah ND; Fried MW
Clin Liver Dis (Hoboken); 2016 Feb; 7(2):40-44. PubMed ID: 31041026
[No Abstract] [Full Text] [Related]
35. The practical management of treatment failure in chronic hepatitis C: a summary of current research and management options for refractory patients.
Hassanein T; Shiffman ML; Zein NN
Gastroenterol Hepatol (N Y); 2007 Jun; 3(6 Suppl 20):4-32. PubMed ID: 23329897
[No Abstract] [Full Text] [Related]
36. Treatment of HCV patients before and after renal transplantation.
Du LY; Tang H
Hepat Mon; 2011 Nov; 11(11):880-6. PubMed ID: 22308151
[TBL] [Abstract][Full Text] [Related]
37. Use of hematopoietic growth factor in the management of hematological side effects associated to antiviral treatment for HCV hepatitis.
Mancino P; Falasca K; Ucciferri C; Pizzigallo E; Vecchiet J
Mediterr J Hematol Infect Dis; 2010 Mar; 2(1):e2010003. PubMed ID: 21415945
[TBL] [Abstract][Full Text] [Related]
38. Review of consensus interferon in the treatment of chronic hepatitis C.
Witthöft T
Biologics; 2008 Dec; 2(4):635-43. PubMed ID: 19707444
[TBL] [Abstract][Full Text] [Related]
39. Managing chronic hepatitis C in the difficult-to-treat patient.
Kemmer N; Neff GW
Liver Int; 2007 Dec; 27(10):1297-310. PubMed ID: 18036096
[TBL] [Abstract][Full Text] [Related]
40. Improvement of quantitative testing of liver function in patients with chronic hepatitis C after installment of antiviral therapy.
Ocker M; Ganslmayer M; Zopf S; Gahr S; Janson C; Hahn EG; Herold C
World J Gastroenterol; 2005 Sep; 11(35):5521-4. PubMed ID: 16222747
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
